medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2015; 67 (2)


Menopausal Women Have Hypofibrinolysis Even in Subclinical Stage of Atherosclerosis

Córdova-Pérez N, Basurto-Acevedo L, Degollado-Córdova JA, Saucedo-García RP, Martínez-Murillo C, Zárate-Treviño A, Vázquez-Martínez AL, Vega-García S, Díaz-Martínez AG, Borrayo-Sánchez G, Reyes-Maldonado E

Idioma: Español
Referencias bibliográficas: 58
Paginas: 122-129
Archivo PDF: 220.17 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121:1768-77.

  2. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404-11.

  3. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the American Heart Association’s Task Force on Risk Reduction. Circulation. 1998;97:1876-87.

  4. Raven GM, Chen YD. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit? Circulation. 1996;93:1780-3.

  5. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-8.

  6. Basurto L, Saucedo R, Zárate A, et al. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol Obstet Invest. 2006;61:61-4.

  7. Moreira L, Das Graças M, Fonseca C, Faria J, Oliveira M. PAI-1 4G/5G polymorphism and plasma levels association in patients with coronary artery disease. Arq Bras Cardiol. 2011;97:462-7.

  8. Naran NH, Chetty N, Crowther NJ. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis. 2008;196:155-63.

  9. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.

  10. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-02.

  11. Rossignol P, Luttun A, Martin-Ventura JL, et al. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost. 2006;4:664-70.

  12. Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007;27:1231-7.

  13. Chen Y, Budd RC, Kelm RJ, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol. 2006;26:1777-83.

  14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.

  15. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000;96:4212-5.

  16. Belcaro G, Geroulakos G, Laurora G, et al. Subclinical arteriosclerosis screening. The PAP/PEA study. Prevalenza dell’Arteriosclerosi Precoce (Prevalence of Early Arteriosclerosis). J Cardiovasc Surg. 1994;35:123-8.

  17. Geroulakos G, O’Gorman D, Nicolaides A, Sheridan D, Elkeles R, Shaper AG. Carotid intima-media thickness: correlation with the British Regional Heart Study risk score. J Intern Med. 1994;235:431-3.

  18. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77-82.

  19. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb Vasc Biol. 1993;13:1412-7.

  20. Raiko JRH, Oikonen M, Wendelin-Saarenhovo M, et al. Plaminogen activator inhibitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2012;224:208-12.

  21. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th Watching the Risk Symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34:290-6.

  22. Escobedo J, Schargrodsky H, Champagne B, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol. 2009;8:52

  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-19.

  24. De la Cruz-Mosso U, Muñoz-Valle JF, Salgado-Bernabé AB, et al. Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children. J Pediatr (Rio J). 2013; 89:492-98.

  25. Alberti KG, Zimmet PZ, Shaw JE. IDF Epidemiology Task Force Consensus Group: The metabolic syndrome: a new world-wide definition from the International Diabetes Federation consensus. Lancet. 2005;366:1059-62.

  26. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.

  27. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation. 1999 18;99:2496-8.

  28. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1979-89.

  29. Simone TM, Higgins PJ. Low molecular weight antagonists of plasminogen activator inhibitor-1: Therapeutic potential in cardiovascular disease. Mol Med Ther. 2012;1:101.

  30. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost. 1999;82:1121-6.

  31. Karasek D, Vaverkova H, Halenka M, et al. Prehypertension in dyslipidemic individuals; relationship to metabolic parameters and intima-media thickness. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:41-9.

  32. Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol. 2009;220:655-63.

  33. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792-801.

  34. Schafer K, Müller K, Hecke A, et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003;23:2097-103.

  35. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718-20.

  36. Gronholdt ML, Dalager-Pedersen S, Falk E. Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J. 1998;19:C24-9.

  37. Davies MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 1996;94:2013-20.

  38. Asztabski M, Wypasek E, Zabczyk M, Undas A. Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increases intima-media thickness in patients with primary antiphospholipid syndrome. Thrombosis Res. 2014;134:945-51.

  39. Robertson CM, Gerry F, Fowkes R, Price JF. Carotid intimamedia thickness and the prediction of vascular events. Vasc Med. 2012;17:239-48.

  40. Li YY. Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis. PLoS One. 2012;7:e33511.

  41. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-67.

  42. Grau M, Subirana I, Agis D, et al. Carotid intima-media thickness in the Spanish population: reference ranges and association with cardiovascular risk factors. Rev Esp Cardiol. 2012;65:1086-93.

  43. Chain S, Luciardi H, Feldman G, Valberdi A. El espesor íntimamedia carotídeo, un marcador de ateroesclerosis subclínica y riesgo cardiovascular. Importancia de su valoración y dificultades en su interpretación. Rev Fed Arg Cardiol. 2005;34:392-402.

  44. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis. 2012;225:180-6.

  45. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Progression rates of carotid intimamedia thickness and adventitial diameter during the menopausal transition. Menopause. 2013;20:8-14.

  46. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med. 2010;28:426-34.

  47. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373-84

  48. Celestino Catão Da Silva D, Nogueira De Almeida Vasconcelos A, Cleto Maria Cerqueira J, et al. Endogenous sex hormones are not associated with subclinical atherosclerosis in menopausal women. Minerva Ginecol. 2013;65:297-302.

  49. Mateo I, Morillas P, Quiles J, et al. What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value? Rev Esp Cardiol. 2011;64:417-20.

  50. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 1999;30:841-50.

  51. Saucedo R, Basurto L, Zárate A, Martínez C, Hernandez M, Galván R. Association of plasminogen activator inhibitor type 1 (PAI-1) with insulin resistance in menopausal women. The effect of estradiol therapy. Gynecol Obstet Invest. 2007;64:61-64.

  52. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 2002;16:1931-42.

  53. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004;53:2735-40.

  54. Sanches P de L, Mello MT, Fonseca FA, et al. Insulin resistance can impair reduction on carotid intima-media thickness in obese adolescents. Arq Bras Cardiol. 2012;99:892-8.

  55. Mauras N, Delgiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab. 2010;95:1060-8

  56. Griffiths SL, Grainger DJ. Proposal of a novel diabetogenic mechanism involving the serpin PAI-1. Bioessays. 2006;28:629-41.

  57. Fox CS, Larson MG, Corey D, et al. Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimal medial thickness. The Framingham Heart Study. Stroke. 2004;35:e65-7.

  58. Bonithon-Kopp C, Touboul PJ, Berr C, et al. Relation of intimamedia thickness to atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study. Arterioscler Thromb Vasc Biol. 1996;16:310-16.




2020     |     www.medigraphic.com